Assessment of chronic myeloid leukemia patients' adherence with “tyrosine kinase inhibitors” in King Abdulaziz Medical City

CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treatment and outcome has improved dramatically from the average survival of 3–5 years in the past to almost normal life expectancy with the new targeted therapy with tyrosine kinase inhibitors (TKI). Comp...

Descripció completa

Dades bibliogràfiques

Autors principals:	Saad Saleh Aldughaythir, Yousef Alolah, Mohsen Alzahrani, Fahad Abdulaziz Alsayed, Bader Muaykil Alqahtani, Omar Abdulrahman Alhathlol
Format:	Artigo
Idioma:	Inglês
Publicat:	Wolters Kluwer Medknow Publications 2017-01-01
Col·lecció:	Journal of Applied Hematology
Matèries:	Chronic myeloid leukemia compliance tyrosine kinase inhibitors
Accés en línia:	http://www.jahjournal.org/article.asp?issn=1658-5127;year=2017;volume=8;issue=4;spage=140;epage=144;aulast=Aldughaythir
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!